Abstract Details

Title Parkinson's Disease Clinical Profile in Cameroon: A Comparison between Spanish and Cameroonian Cohorts

Topic Movement Disorders

Presentation(s) P03 - (-)

Poster/Presentation
Number 066

Objective

Background BACKGROUND: Current data on the clinical profile of Parkinson's disease (PD) in sub-Saharan patients with limited and intermittent access to dopaminergic drugs are sparse.

Design/Methods DESIGN/METHODS: Observational, cross-sectional design. Clinical and demographic data were collected using structured questionnaires and compared between the 2 groups. Disease and motor severity were assessed using the Hoehn and Yahr staging, SCOPA-Motor; autonomic features using the SCOPA-AUT; cognition using the SCOPA-Cognition; comorbidity using the Cumulative Illness Rating Scale-Geriatrics; psychosis using the modified Parkinson Psychosis Rating Scale; anxiety-depression using the Hospital Anxiety and Depression Scale; sleep using SCOPA-Sleep; psychosocial impairment using SCOPA-Psychosocial; pain and fatigue visual analogue scales, and patients'quality of life using EQ-5D.

Results RESULTS: Seventy four patients with idiopathic PD were included (37 from each country) with a mean age of 64.4 + 10.5 years, 70.3% males, and mean disease duration of 5.6 + 5.9 years. Overall, Cameroonians were intermittently treated with antiparkinsonians drugs. Compared to the Spanish PD cohort, Cameroonians were on anticholinergics more frequently (p=0.005), dopaminergic agonists less frequently (p<0.001), and had a trend for taking a lower dose of levodopa (p=0.06). Cameroonians were more severely impaired in terms of motor (HY stage, p=0.03; Scopa-Motor, p<0.001), and cognitive status (p<0.001), anxiety and depression (p<0.001), psychosis (p=0.008), somnolence, fatigue and pain (p<0.001, respectively), psychosocial impairment (p<0.001) and quality of life (p=0.002). Instead, autonomic, comorbidity, and nocturnal sleep problems were similarly found.

Conclusions CONCLUSIONS: Limited and intermittent access to dopaminergic drugs have a dramatic negative impact on PD motor and non motor symptoms, and patients'quality of life.

Authors/Disclosures
Esther Cubo Delgado, MD, PhD, FAAN (Fundacion Burgos Investigacion Salud CIF G09254616) PRESENTER	Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Cubo Delgado has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon. Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Cubo Delgado has received research support from Spanish health ministry. The institution of Dr. Cubo Delgado has received research support from European union grant.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Yael Cohen	Yael Cohen has nothing to disclose.
Maria-Jose Catalan, MD, PhD (H. Clinico San Carlos)	No disclosure on file

��ɫ��

��ɫ��